Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
PARSIPPANY, N.J., Oct. 17, 2017 -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) today announced that Jack Stover, the Company’s President and CEO is scheduled to present on Thursday October 19th at 11:30 am ET at the Dawson James Securities 3rd Annual Small Cap Growth Conference at the Wyndham Grand Jupiter at Harbourside Place, Jupiter, Florida. One-on-one meetings will be held throughout the conference.
About Interpace Diagnostics Group, Inc.
Interpace Diagnostics is a fully integrated commercial company that provides clinically useful molecular diagnostic tests and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for better patient diagnosis and management. The Company currently has four commercialized molecular tests; PancraGEN® for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay and ThyraMIR®, for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and MVPdX that helps differentiates the local recurrence of lung cancer versus new primary cancer formation. Interpace Diagnostics' mission is to provide personalized medicine through molecular diagnostics and innovation to advance patient care based on rigorous science. For more information please visit the Company’s website at www.interpacediagnostics.com.
CONTACTS:
Interpace Diagnostics
Investor Relations:
Paul Kuntz – Redchip
[email protected]
